AgingResearch.NewsJoin free

Thiogenesis Therapeutics

CompanyCanadaFounded 2018

Thiogenesis Therapeutics develops one asset, in phase 2 (TTI-0102 in mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes). Mostly small molecule acting on ACE2; based in Canada, founded in 2018.

1
Asset
Furthest stage
Phase 2
Raised
US$19.1m
0
Trials
0
Signals

Pipeline

1

  • TTI-0102

    Sustained-release cysteamine prodrug that depletes cystine and supports intracellular cysteine and glutathione production.

    Phase 2, Small molecule, ACE2, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, nephropathic cystinosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants7
  • People9
  • Signals2
  • Similar companies6

Intelligence